A recent press release by Intuitive announced that the U.S. FDA cleared the Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.
Editor's Note: This article originally appeared on Intuitive's website.
Intuitive Surgical, Inc. (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) cleared the Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.
Lung cancer is the world’s leading cause of cancer deaths. Many suspicious lesions found in the lung may be small and difficult to access, which can make obtaining a diagnosis challenging.
“Early lung cancer diagnosis can save lives. Intuitive’s advanced, robotic-assisted, minimally invasive Ion system helps address a challenging aspect of lung biopsy by enabling physicians to obtain tissue samples from deep within the lung,” said Gary Guthart, Intuitive CEO. Click here to continue>>
News From Our Partners